Funding News
India's Femtech Sector Has Raised Over Rs 550 Crore in 2026 Alone — Nua, Pee Safe, and Healthfab Define a Maturing Category That Is Finally Getting the Capital It Deserves
By Mustafa Shariff, Editor in Chief · September 22,2026 · 2 mins read
Summary
- India Femtech 2026: Rs 550 Crore Raised by Nua, Pee Safe, Healthfab — The Women's Wellness Investment Wave Has Finally Arrived
- India's femtech sector raised Rs 550 crore+ in 2026: Nua $50M (Peak XV+Filter), Pee Safe $32M (OrbiMed), Healthfab Rs 20Cr (Series A) — confirming institutional conviction in India's women's health and wellness market across period care, intimate care, and menstrual wellness.
"The women's health and wellness investment story in India is not a 2026 story — it is a story that has been building for a decade and has finally reached institutional scale. The category was held back not by lack of demand (half the population is the market) or lack of founders (women entrepreneurs built most of these companies) but by lack of investor conviction. That conviction has now arrived — driven by unit economics that work, by consumer adoption curves that are clear, and by founders who have demonstrated that they can build large businesses in categories that healthcare and consumer investors once dismissed. Rs 550 crore in 2026 is the beginning, not the peak."
India's femtech and women's wellness sector has attracted over Rs 550 crore in confirmed funding in calendar year 2026 — a watershed year for a category that has historically attracted a fraction of the institutional capital deployed into comparable market opportunities in consumer health.
The Three Rounds That Define 2026 India Femtech
Three funding rounds across 2026 define the year's femtech narrative. Pee Safe raised $32 million (approximately Rs 268 crore) from OrbiMed — the global healthcare-focused investment firm — in January 2026. Pee Safe's focus is personal hygiene and intimate care, with a particular emphasis on expanding its offline retail presence across modern trade and pharmacies while scaling on quick commerce platforms. OrbiMed's investment, from a healthcare-specialist fund, signals that femtech in India is attracting the quality of institutional capital that typically goes to clinical-stage pharma and medtech companies.
Healthfab raised Rs 20 crore in a Series A round in May 2026 to expand its menstrual wellness product portfolio. Healthfab's focus on period care products beyond disposable pads — including reusable period underwear and menstrual cups — represents the sustainability and premium-value dimension of India's women's wellness market.
And now Nua's $50 million Series C (covered in story #1 of today's edition) — the largest femtech round in India's history — confirms that the category has reached institutional funding scale. ARR Rs 500 crore, profitable, Peak XV-backed.
What These Rounds Have in Common
All three 2026 femtech rounds share a common commercial DNA: they are businesses with demonstrated unit economics, not early-stage experiments. Nua is profitable at Rs 500 crore ARR. Pee Safe was already a significant business before its OrbiMed round. Healthfab had commercial traction before its Series A. The institutional capital that arrived in 2026 is following commercial validation, not leading it — which is exactly the pattern that precedes a category's mainstream investment moment.
BHC Perspective
At Bengaluru Health Community, India's 2026 femtech funding wave is directly relevant to BHC's women's health ecosystem. For BHC founders building in women's health — the Rs 550 crore raised in 2026 demonstrates that the commercial and investment infrastructure for the category has arrived. The BHC podcast 'She Wasn't Told' — focused on women's health experiences that healthcare systems have historically ignored — is the editorial dimension of exactly the same insight.
FAQs
Q: How much has India femtech raised in 2026?
A: Over Rs 550 crore ($65M+) in confirmed rounds: Nua $50M Series C (September, Peak XV+Filter), Pee Safe $32M (January, OrbiMed), Healthfab Rs 20Cr Series A (May) — the largest single-year femtech funding total in India's startup history.
Q: What do these three rounds have in common?
A: All three backed businesses with proven unit economics and commercial traction before institutional funding: Nua (profitable at Rs 500Cr ARR), Pee Safe (established brand), Healthfab (Series A with commercial traction). Institutional capital is following validation, not leading it.
Q: Why is 2026 different for India femtech?
A: Institutional conviction has arrived: OrbiMed (healthcare specialist) backing Pee Safe, Peak XV (top-tier VC) leading Nua's Series C — quality of investors signals category recognition. Combined with demonstrated profitability and growth, the category has crossed the threshold where it attracts systematic institutional capital.